ITI Life Sciences Launches New Stem Cell Technology Program
A new ?9.5 million R&D program has been launched by ITI Life Sciences (Dundee, Scotland, www.itilifesciences.com) to develop an automated process to produce high-quality human stem cells.
A new £9.5 million R&D program has been launched by ITI Life Sciences (Dundee, Scotland, www.itilifesciences.com) to develop an automated process to produce high-quality human stem cells. This capability will put Scotland at the forefront of stem cell research as well as bring closer the use of stem cells as therapeutics.
As part of this three-year program, the Swedish biotech company Cellartis AB, a stem cell company and a provider of ethically derived human embryonic stem cell (hES) lines, is setting up an R&D and manufacturing facility in Dundee.
The ITI program will also involve the University of Glasgow, which brings expertise in the molecular mechanisms that control cell signaling and development. The work will be carried out by the University’s Faculty of Medicine and Faculty of Biomedical and Life Sciences. In creating this program, ITI Life Science hopes to solve some of the main problems associated with producing high volumes of quality stem cells.
The ITI program will use pre-existing hES cell lines. This phase of the program will be deemed a success if it results in a robust and standardized procedure for generating multiple human cell lines of interest to the pharmaceutical industry from undifferentiated hES cells. ITI Life Sciences will own all intellectual property generated by the program.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
